Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
One offers a more affordable entry point while the other boasts some of the highest profit margins in the sector. The choice comes down to whether you prioritize income stability or growth potential.
Overview
Biotechnology investors often compare the steady cash flows of established giants with the explosive potential of specialized innovators. Choosing between Amgen (NASDAQ:AMGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) requires balancing scale against high-margin specialization.
Amgen operates as a global pharmaceutical titan with a massive portfolio spanning multiple therapeutic areas. Vertex focuses on transformative therapies for rare diseases, historically dominating the cystic fibrosis market. Comparing these two involves choosing between a diversified income-generating giant and a focused biotech specialist with an expanding pipeline.
Details
Amgen discovers and develops medicines for serious diseases across oncology, inflammation, and rare disease categories. The company distributes its products globally, relying heavily on its primary partners McKesson (NYSE:MCK), Cencora (NYSE:COR), and Cardinal Health (NYSE:CAH). These three distributors accounted for nearly 77% of worldwide gross revenues in 2025, which represents a significant customer concentration risk.
Source
Originally published at www.fool.com.